Drugs / SPR741
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03376529 | Nov → Dec 2017 | — | Spero Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03022175 | Dec 2016 → Jul 2017 | — | Spero Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2018-05-23 | Sperotx | Results Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform sperotx.com ↗
The single dose data indicate that the administration of b-lactam antibiotics had no impact on PK or tolerability of SPR741, supporting further development of SPR741 as a combination agent for the treatment of MDR infections. |
| 2018-04-16 | Sperotx | Results Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases sperotx.com ↗
SPR741, administered up to 400 mg every 8 hours for up to 14 days, displayed linear and proportional pharmacokinetics and showed no evidence of accumulation or time dependent changes in plasma exposure as measured by AUC, Cmax or Ctrough. |
All press releases naming this drug 3 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPR741 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03022175 ↗ |
| Known as | NAB-741 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1631770 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1631770 ↗ |
| Route | Intravenous | “single and multiple intravenous doses of SPR741” NCT03022175 ↗ |